Diabetic Foot Ulcers – Pipeline Review, 2019

Diabetic foot ulcer is a complication occurring because of poorly controlled diabetes, causing foot injuries leading to lower extremity amputation. Patients with diabetes neuropathy and diabetic nerve pain are closely linked and are at a higher risk of developing open sore wounds. When the blood sugar levels are high or fluctuate regularly, skin wounds that would normally heal may not properly repair itself because of nerve damage leading to severe wounds or foot ulcers. Foot ulcers affect people with diabetes type 1 and type 2. Symptoms include loss of ability to feel pain, blisters, or other wounds without pain, skin discoloration, redness, and swelling. Complications in foot ulcers may result in wounds that may not heal, skin infections, abscesses, and foot deformity.

Current treatment of diabetic foot ulcers includes medications, cleaning, and dressing of wounds. Medications for diabetic foot ulcers include antibiotics, antiplatelets, or anti-clotting drugs. Topical treatments such as silver sulphadiazine cream, Polyhexamethylene Biguanide (PHMB) gel or solutions, and others are being used initially to treat infections in diabetic foot ulcers. When non-surgical treatments are unsuccessful in healing foot ulcers, surgical treatment is recommended that includes removal of decaying tissue, amputation, and endovascular surgery.

Pharmaceutical and biotechnology companies, along with various research institutes are focusing on studying and developing advanced treatment options for diabetic foot ulcers. For instance; CSTC1 studied by Charsire Biotechnology Corp., is currently in phase-2 clinical trials for the study of safety and efficacy of CSTC1 in patients with diabetic foot ulcers.

At present, around 30% of the pipeline candidates for diabetic foot ulcers are in the phase-2 clinical stage. Maximum studies are sponsored by pharmaceutical and biotechnology industries.

Report Description

The report on ‘Diabetic Foot Ulcers – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Diabetic Foot Ulcers. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Diabetic Foot Ulcers.

The report on ‘Diabetic Foot Ulcers – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Diabetic Foot Ulcers.


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Diabetic Foot Ulcers.


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary